Cambridge, MA, April 8, 2017 -- Aurora BioPharma, Inc., a clinical stage biotechnology company developing a breakthrough in cancer treatment, announced today that company CEO and President, Robert Brooks, will join in on a presentation and discussion of the GBM AGILE (Adaptive, Global, Innovative, Learning Environment) trial. The meeting is being held at the Ritz Carlton, at Fashion Centre at Pentagon City, April 11th.
GBM AGILE is being developed through the National Biomarker Development Alliance (NBDA), a non-profit organization created as part of the Research Collaboratory at Arizona State University (ASU). The NBDA's mission is to collaboratively create standards-based, end-to-end systems solutions for biomarker discovery, development and delivery to advance precision medicine. The NBDA operates through trans-disciplinary and trans-sector networks to develop new research networks and consortia that focus on "demonstration projects" that advance all aspects of biomarker research and applications - especially developing smarter and more efficient clinical trials. Although NBDA is generally disease agnostic, rare diseases like GBM are a focus for the Alliance since in most cases few if any biomarkers exist and most clinical trials fail. Overall, the NBDA is dedicated to moving high quality, effective biomarkers through all phases of discovery, development and validation through more innovative and efficient clinical trials to ensure that the promise of precision (molecularly based) medicine will be available to all patients.
Aurora is leading in the development of Chimeric Antigen Receptor (CAR) T therapy, with an extensive clinical pipeline. Osteosarcoma is the most common type of bone cancer in Children and Adolescents, even after radical amputation of a limb and chemotherapy, survival is poor. A completed Phase I/IIa trial in 19 Sarcoma (16 Osteosarcoma) patients was completed, Aurora's CAR T agent AU-101 met its endpoints of safety, with strong signs of tumor killing efficacy, and long term survivors. Glioblastoma is the most common and deadliest form of brain cancer. Aurora's CAR T agent AU105 showed in a completed Phase I/IIa clinical trial in 16 Glioblastoma patients, safety, tumor killing efficacy, and double the median historic overall survival. Aurora is planning a randomized multi-site Phase II trial of AU105 in Early Diagnosed Glioblastoma, and a Phase I/II trial in Recurrent Glioblastoma with intracranial injection. Aurora is planning a Phase II trial of its CAR T Cell therapy AU105 in Osteosarcoma.
The electronic message you received is confidential and may be legally privileged or otherwise protected from disclosure. If you are not the intended recipient, please call or email the sender and delete this message and any attachment from your system; you must not copy or disclose the contents of this message or any attachment to any other person.
This is not an offer or a solicitation of an offer to purchase or sell any security. Statements in this message that are not based on historical or current facts, including without limitation statements such as the words "anticipates," "believes," "may," "continues," "estimates," "expects," and "will" constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Although Aurora BioPharma, Inc. believes that expectations conveyed by the forward-looking statements are reasonable based on the information available to it on the date such statements were made, no assurances can be given as to the future results, approvals or achievements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements, and should assume the Company has no obligation to update forward-looking statements except as otherwise required by applicable law.
Aurora BioPharma, Inc.
Tel: (617) 674-7718 - Fax: (617) 674-7701
SOURCE Aurora BioPharma, Inc.